This appeal was not successful at this stage
The AAO dismissed the appeal because the petitioner met only two of the required three evidentiary criteria (judging and scholarly articles), failing to establish the original contributions of major significance criterion. Without meeting the three-criteria threshold, no final merits determination was required.
1 more criterion would trigger a full merits review.
A research senior specialist in pharmacochemistry and pharmaceutical sciences sought EB-1A classification, claiming extraordinary ability through peer review activity, scholarly publications, and original contributions in cancer drug delivery, cell isolation, preterm birth treatment, transplant pharmacokinetics, and a novel amino acid probe. The AAO agreed with the Director that the petitioner met the judging and scholarly articles criteria but found the original contributions criterion unmet. Expert letters were deemed conclusory and hyperbolic, citation statistics were insufficient to show major field impact without additional context, and some factual claims by supporting experts were directly contradicted by the petitioner's own published research. Because the petitioner failed to meet the three-criteria threshold, no final merits determination was conducted, and the appeal was dismissed.
What worked: The petitioner successfully demonstrated participation in peer review of manuscripts and authorship of scholarly articles in reputable journals, satisfying two of the three required criteria.
What failed: Expert opinion letters supporting the original contributions claim were too conclusory and failed to explain how the petitioner's work was widely implemented or had a field-wide impact. Citation metrics (top 10% rankings, cumulative totals) were held insufficient without specific evidence of major significance. Several expert claims were undermined by the petitioner's own published articles, which credited other researchers for foundational methodologies or described less transformative findings than the letters suggested.
Takeaway: For the original contributions criterion, petitioners should provide concrete, verifiable examples of how their specific work has been widely adopted, changed practices, or influenced the field beyond a circle of direct collaborators—general praise and citation counts alone will not suffice. Expert letters must be consistent with the petitioner's own published findings and should explain the mechanism and scale of real-world impact.
Cases like this are frequently used by attorneys when responding to RFEs or building initial petitions. The evidence patterns that worked (or failed) here directly reflect what USCIS officers look for when evaluating EB-1A criteria.
● Evidence that moved the needle
- The petitioner successfully demonstrated participation in peer review of manuscripts and authorship of scholarly articles in reputable journals, satisfying two of the three required criteria.
● Evidence that wasn't enough alone
- Expert opinion letters supporting the original contributions claim were too conclusory and failed to explain how the petitioner's work was widely implemented or had a field-wide impact
- Citation metrics (top 10% rankings, cumulative totals) were held insufficient without specific evidence of major significance
- Several expert claims were undermined by the petitioner's own published articles, which credited other researchers for foundational methodologies or described less transformative findings than the letters suggested.
Criterion-by-criterion breakdown
Judging the work of others
MetPetitioner peer-reviewed manuscripts for journals including Acta Biomateriala and Journal of Bioanalysis & Biomedicine; AAO agreed with Director that this criterion was met.
Original contributions of major significance
Not metPetitioner claimed major significance through cancer drug delivery, cell isolation methodology, pre-term birth research, transplant pharmacokinetics, and amino acid probe development. AAO found expert letters conclusory, citation evidence insufficient to show widespread implementation or remarkable field impact, and some factual claims contradicted by the petitioner's own published articles.
Authorship of scholarly articles
MetPetitioner authored articles in Biomaterials, Acta Biomateriala, Hepatology, American Journal of Obstetrics & Gynecology, Nature Communications, and Cell Transplantation; AAO agreed this criterion was met.
Peer review of manuscripts for Acta Biomateriala and Journal of Bioanalysis & Biomedicine (judging criterion met)
Scholarly articles published in Biomaterials, Acta Biomateriala, Hepatology, American Journal of Obstetrics & Gynecology, Nature Communications, and Cell Transplantation (scholarly articles criterion met)
Expert opinion letters regarding original contributions: found to be conclusory, hyperbolic, and lacking specific examples of major significance or widespread implementation
Google Scholar and Clarivate Analytics citation statistics: top-10% citation ranking held insufficient to establish major significance without additional context
Microsoft Academic cumulative citation comparisons: aggregate data did not demonstrate any specific work of major significance
University patents citing petitioner's papers: petitioner not listed as inventor; patents recognize originality but not major significance
Review article citations: petitioner's articles cited among dozens or hundreds of others without distinction or acknowledgment of special impact
Expert letter claiming petitioner developed a cost-effective progesterone treatment for preterm birth: contradicted by petitioner's own published article, which evaluated existing compounded pharmacy products rather than developing a new treatment
Expert letters on cell isolation methodology: petitioner's own article credited other researchers with developing the core isolation procedure
Notable citation examples: citing articles did not distinguish petitioner's work or highlight its singular importance
Completed
I-140 filed
Research senior specialist in pharmacochemistry and pharmaceutical sciences, specializing in pharmacokinetics and drug analysis
Completed
Director — Denied
Initial decision: Denied.
Completed
Appeal to the AAO
Petitioner appealed to the Administrative Appeals Office for de novo review.
2020-01-22
AAO decision — Dismissed
The AAO dismissed the appeal because the petitioner met only two of the required three evidentiary criteria (judging and scholarly articles), failing to establish the original contributions of major significance criterion. Without meeting the three-criteria threshold, no final merits determination was required.
If you're appealing a similar decision, I-290B must be filed within 30 days of personal service of the denial, or 33 days if mailed.
Find this useful? A coffee helps keep Case Reviewer free and ad-free.
Buy me a coffee